Page URL: https://www.bionews.org.uk/page_95366

CRISPR corrects mutation that causes blindness

1 February 2016
Appeared in BioNews 837

Researchers have used the CRISPR/Cas9 genome-editing technique to correct a genetic mutation that causes blindness.

The study, published in Scientific Reports, used CRISPR/Cas9 to correct a mutation in cells derived from patients with retinitis pigmentosa (RP), thereby creating a source of therapeutic cells with a very low risk of rejection.

'Our vision is to develop a personalised approach to treating eye disease,' said study co-author Dr Stephen Tsang of Columbia University Medical Centre. He added, 'We still have some way to go, but we believe that the first therapeutic use of CRISPR will be to treat an eye disease. Here we have demonstrated that the initial steps are feasible.'

RP is a genetic disorder affecting approximately 1 in 4000 people, in which light-sensing cells in the retina degenerate, resulting in tunnel vision and eventually total sight loss. Currently, there is no cure for RP although recent gene-therapy and stem-cell studies have shown some promise (see BioNews 603 and 784).

The team reprogrammed skin cells to become induced pluripotent stem cells, and then used CRISPR/Cas9 to pinpoint and repair a defective mutation in the RPGR gene, which causes the aggressive X-linked variant of RP. 'The X-linked form of retinitis pigmentosa is an ideal candidate for a precision medicine approach because a common mutation accounts for 90 percent of cases,' Dr Tsang explained.

The team was not sure whether the CRISPR technology would be able to home in on and correct the genetic mutation since it sits in a highly repetitive sequence of the RPGR gene, making it difficult to discriminate from one region from another. Despite these difficulties, they were able to correct the genetic mutation in 13 percent of the stem cells.

The researchers say that the present study is an important proof-of-concept, demonstrating personalised and precision medicine through the repair of a mutation using genome-edited stem cells. Non-CRISPR gene therapies are undergoing clinical trials but these do not permanently correct the defective gene, and initial gains in retinal sensitivity gradually diminish over time.

Dr Tsang said that there is more work to do before clinical trials can begin using the technique. 'Before we go into patients, we want to make sure we are only changing that particular single mutation, and we are not making other alterations to the genome,' he said.

SOURCES & REFERENCES
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
9 October 2017 - by Dr Kimberley Bryon-Dodd 
Gene therapy has restored some vision in mice blinded by retinitis pigmentosa, an inherited degenerative eye disease...
21 November 2016 - by Paul Waldron 
Scientists in the US have used a genome-editing technique to partially restore vision in blind rats...
3 May 2016 - by Sarah Gregory 
A trial of gene therapy for choroideremia, a rare form of inherited blindness, has partially restored the vision of several patients...
25 April 2016 - by Dr Özge Özkaya 
Scientists have fine tuned the genome-editing tool CRISPR so that it can now edit a single 'letter' of DNA...
7 March 2016 - by Kirsty Oswald 
Researchers have found that mimiviruses, a class of giant viruses, have an immune system reminiscent of the CRISPR system used by bacteria to evade infection...
11 January 2016 - by Paul Waldron 
Researchers have improved the genome-editing technique CRISPR/Cas9, reducing errors to nearly undetectable levels, according to a new study...
11 January 2016 - by Jenny Sharpe 
Scientists in the USA have shown that the genome-editing technique CRISPR can improve muscle function in a mouse model of Duchenne muscular dystrophy...
9 November 2015 - by Lone Hørlyck 
An experimental cell-based treatment using gene editing, previously only tested on mice, has successfully reversed advanced leukaemia in a one-year-old girl...
15 December 2014 - by Dr Rosie Gilchrist 
Scientists have used gene therapy to restore some sight to animals with visual impairment similar to retinosa pigmentosa, a type of human blindness...
11 April 2011 - by Dr Rachael Panizzo 
Embryonic stem cells have been used to generate a basic retina, the part of the eye that detects light and is needed for vision. The retinal tissue could be used to treat some forms of blindness, such as retinitis pigmentosa and age-related macular degeneration, and to investigate and screen potential new drugs for a range of eye diseases....
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.